Lilly Defeats Cymbalta Label Suit As Possible MDL Looms
Law360, San Diego (November 7, 2014, 8:40 PM EST) -- A New York federal judge on Friday ruled Eli Lilly & Co.’s label for antidepressant drug Cymbalta adequately warned doctors about possible withdrawal symptoms and tossed a suit claiming the label was inaccurate, potentially hurting the plaintiffs’ chances to consolidate more than two dozen similar cases in multidistrict litigation.
U.S. District Judge Robert W. Sweet granted Eli Lilly's summary judgment bid, finding its label properly described the potential negative effects of stopping the drug and did not mislead medical professionals. The judge also ruled that plaintiff Jesse McDowell’s doctor knew about the risks, having seen at least half her patients experience...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!